1. Home
  2. BPTH vs ADD Comparison

BPTH vs ADD Comparison

Compare BPTH & ADD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPTH
  • ADD
  • Stock Information
  • Founded
  • BPTH 2007
  • ADD 2002
  • Country
  • BPTH United States
  • ADD United States
  • Employees
  • BPTH N/A
  • ADD N/A
  • Industry
  • BPTH Biotechnology: Pharmaceutical Preparations
  • ADD Engineering & Construction
  • Sector
  • BPTH Health Care
  • ADD Consumer Discretionary
  • Exchange
  • BPTH Nasdaq
  • ADD Nasdaq
  • Market Cap
  • BPTH 5.0M
  • ADD 2.4M
  • IPO Year
  • BPTH N/A
  • ADD N/A
  • Fundamental
  • Price
  • BPTH $1.09
  • ADD $2.02
  • Analyst Decision
  • BPTH Strong Buy
  • ADD
  • Analyst Count
  • BPTH 2
  • ADD 0
  • Target Price
  • BPTH $30.00
  • ADD N/A
  • AVG Volume (30 Days)
  • BPTH 6.2M
  • ADD 3.0M
  • Earning Date
  • BPTH 11-15-2024
  • ADD 01-17-2025
  • Dividend Yield
  • BPTH N/A
  • ADD N/A
  • EPS Growth
  • BPTH N/A
  • ADD N/A
  • EPS
  • BPTH N/A
  • ADD N/A
  • Revenue
  • BPTH N/A
  • ADD $2,830,442.00
  • Revenue This Year
  • BPTH N/A
  • ADD N/A
  • Revenue Next Year
  • BPTH N/A
  • ADD N/A
  • P/E Ratio
  • BPTH N/A
  • ADD N/A
  • Revenue Growth
  • BPTH N/A
  • ADD N/A
  • 52 Week Low
  • BPTH $0.59
  • ADD $1.88
  • 52 Week High
  • BPTH $12.00
  • ADD $185.00
  • Technical
  • Relative Strength Index (RSI)
  • BPTH 54.13
  • ADD 29.73
  • Support Level
  • BPTH $1.11
  • ADD $1.98
  • Resistance Level
  • BPTH $1.34
  • ADD $2.86
  • Average True Range (ATR)
  • BPTH 0.30
  • ADD 0.50
  • MACD
  • BPTH 0.02
  • ADD 0.61
  • Stochastic Oscillator
  • BPTH 16.36
  • ADD 5.67

About BPTH Bio-Path Holdings Inc.

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

About ADD Color Star Technology Co. Ltd.

Color Star Technology Co Ltd is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.

Share on Social Networks: